VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026Munich, Germany, March 25, 2026 (GLOBE NEWSWIRE) -- VeonGen Therapeutics, a clinical-stage genetic medicine company developing next-generation gene therapies, today announced clinical progress of VG801, with an oral presentation at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 3-7 in Denver, Colorado.
